The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...